Neil Gregory Almstead - Feb 15, 2024 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
CHIEF TECHNICAL OPS OFFICER
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Feb 15, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 05:00 PM
Previous filing
Feb 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Award $0 +19K +31.04% $0.00 80.2K Feb 15, 2024 Direct F1
transaction PTCT Common Stock Award $0 +6K +7.48% $0.00 86.2K Feb 15, 2024 Direct F2
transaction PTCT Common Stock Award $0 +870 +23.48% $0.00 4.58K Feb 15, 2024 By Spouse F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Award $0 +47.5K $0.00 47.5K Feb 15, 2024 Common Stock 47.5K $25.69 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025.
F2 Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025.
F3 Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025.
F4 This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.